ANNAPOLIS, Md., March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today reported the company will delay its earnings release for the full year ended December 31, 2007. The earnings release was previously scheduled for today, March 20, 2008. PharmAthene will schedule the new date and time of its earnings release and conference call at a later time.
The conference call originally scheduled to discuss earnings will occur at 4:30 pm E.T. today and will focus on the Avecia acquisition announced earlier today.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.PharmAthene.com.
CONTACT: Stacey Jurchison of PharmAthene, Inc., +1-410-269-2610,
JurchisonS@PharmAthene.com
Web site: http://www.pharmathene.com/
